TRV-120027

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameTRV-120027
Drug Alias Nameβ-arrestin biased ligandBeta-arrestin biased ligandTRV-027MPS-418TRV-120027
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acutely decompensated congestive heart failureHeart Failure +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTrevena Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthNational Heart, Lung, And Blood Institute (Nhlbi)Forest Laboratories Inc
Inactive CompaniesTrevena Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsAcutely decompensated congestive heart failureHeart FailureKidney Diseases

Other Information

ATC CodeN/A
Related LinksN/A